BCL2抑制剂Venetoclax联合化疗在3例复发难治急性髓系白血病中的应用及文献复习

宗香萍; 杨贞; 周进; 李静; 李彩霞; 吴德沛

doi:10.13201/j.issn.1004-2806.2021.07.013

BCL2抑制剂Venetoclax联合化疗在3例复发难治急性髓系白血病中的应用及文献复习

- 苏州大学附属第一医院血液科(江苏苏州, 215006)
基金项目:
国家科技重大专项课题(No:2017ZX09304021)

国家重点研发计划(No:2019YFC0840604,2017YFA0104502)

江苏省重点研发计划(No:BE2019798)

江苏省医学杰出人才项目(No:JCRCA2016002)

江苏省科教强卫工程-临床医学中心(No:YXZXA2016002)

详细信息

通讯作者: 李彩霞,E-mail:licaixia@suda.edu.cn

中图分类号: R733.71

收稿日期: 2019-09-11

Application of BCL2inhibitor Venetoclax combined with chemotherapy in three recurrent and refractory acute myeloid leukemia patients and literature review

More Information

Corresponding author: LI Caixia, E-mail: licaixia@suda.edu.cn

Received Date: 11 September 2019

摘要

- 复发难治急性髓系白血病 /
- BCL2抑制剂 /
- Venetoclax
- refractory/recurrent acute myeloid leukemia /
- BCL2 inhibitor /
- Venetoclax

HTML全文

参考文献(14)

[1]	Sarkozy C,Gardin C,Gachard N,et al.Outcome of older patients with acute myeloid leukemia in first relapse[J].Am J Hematol,2013,88(9):758-764.
[2]	Tsujimoto Y,Cossman J,Jaffe E.Involvement of the bcl-2 gene in human follicular lymphoma[J].Science,1985,228(4706):1440-1443.
[3]	Mehta SV,Shukla SN,Vora HH.Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia:its correlation with FLT3[J].Neoplasma,2013,60(6):666-675.
[4]	Del Poeta G,Venditti A,Del Principe MI,et al.Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia(AML)[J].Blood,2003,101(6):2125-2131.
[5]	Pan R,Hogdal LJ,Benito JM,et al.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J].Cancer Discov,2014,4(3):362-375.
[6]	Konopleva M,Pollyea DA,Potluri J,et al.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia[J].Cancer Discov,2016,6(10):1106-1117.
[7]	DiNardo CD,Pratz K,Pullarkat V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia[J].Blood,2019,133(1):7-17.
[8]	Wei A,Strickland SA,Roboz GJ,et al.Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive,Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy:1-Year Outcomes[J].Blood,2017,130(Suppl 1):890-890.
[9]	Kontro M,Kumar A,Majumder MM,et al.HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia[J].Leukemia,2017,31(2):301-309.
[10]	Pollyea DA,Stevens BM,Jones CL,et al.Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia[J].Nat Med,2018,24(12):1859-1866.
[11]	Karjalainen R,Pemovska T,Popa M,et al.JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML[J].Blood,2017,130(6):789-802.
[12]	Lehmann C,Friess T,Birzele F,et al.Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models[J].J Hematol Oncol,2016,9(1):50.
[13]	Han L,Zhang Q,Shi C,et al.Concomitantly Targeting BCL-2 with Venetoclax(ABT-199/GDC0199) and MAPK Signaling with Cobimetinib(GDC-0973) in Acute Myeloid Leukemia Models[J].Blood,2015,126(23):2544-2544.
[14]	Fischer MA,Friedlander S,Hogdal L,et al.Combination of Selective Inhibitor of Nuclear Export(SINE)Compounds,Selinexor and KPT-8602,with Venetoclax(ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma[J].Blood,2016,128(22):3949-3949.